New drug combo for advanced lung cancer with EGFR
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests two new drugs (Becotatug vedotin and Pucotenlimab), with or without radiation, as the first treatment for advanced lung cancer that has a specific protein marker (EGFR). The goal is to see if this combination can shrink tumors and help people live longer without their cancer growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your lung cancer must be stage IV (spread to other parts of the body).
- You cannot have received any previous treatment for advanced lung cancer (except if you finished chemotherapy or radiation more than 6 months ago as an early treatment).
- Your tumor must have a high level of a protein called EGFR (2+ or higher), and cannot have certain genetic changes like EGFR, ALK, or ROS1.
- You need to be in good physical condition (able to do light work or be up and about).
- You cannot have had certain bleeding problems, major heart issues, or untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination of drugs given before surgery (neoadjuvant) and followed by radiation after surgery to treat locally advanced head and neck cancer. The goal is to see if this approach is safe and effective, and may improve outcomes for patients who have not yet been treated.
This trial tests a new combination of two drugs—Becotatug Vedotin (a targeted therapy that delivers chemotherapy directly to EGFR-positive cancer cells) and Pucotenlimab (an immunotherapy that helps your immune system fight cancer). It is for people with advanced solid tumors that have not responded to standard treatments.
This trial tests a new combination of drugs for a type of head and neck cancer that has a specific protein called EGFR. The treatment combines an antibody-drug conjugate, an immunotherapy, and standard chemotherapy. The goal is to see if this combination shrinks or controls the cancer before possible surgery.
This trial tests a new combination of two drugs for people with advanced head and neck cancer who cannot take standard platinum chemotherapy. The goal is to see if this treatment can help control the cancer and improve outcomes.
This trial tests a combination of two new drugs—an immunotherapy and an antibody-drug conjugate—for people with advanced squamous cell carcinoma of the skin. The goal is to see if this combo can shrink tumors and slow the cancer.
This trial tests two drugs — becotatug vedotin and pucotenlimab — together in people with advanced penile cancer whose tumors show a protein called EGFR. It aims to see if this combination can shrink or slow the cancer.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.